Module Delivery Systems
A number of model candidates that are highly potent and have low therapeutic indication can be targeted to the required diseased site using the appropriate delivery system. For instance, some drugs encapsulated in liposomes can have a significantly altered pharmacokinetics. Creative Biolabs provides customized targeted delivery services by advanced technical platform to assist in your research. Our scientists, equipped with extensive experience in biologics production, synthetic chemistry, and bio-conjugation, are committed to providing high-quality services to promote the development of innovative cancer treatments.
Delivering Module
Targeted delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in the targeted parts of the body. Although the use of peptides or scaffold proteins as drugs has shown some success and early promise, the limitations are inevitable, i.e. peptides usually subject to a rapid clearance and a short half-life. Thus, the targeted delivery system is a promising strategy to extend stability and improve drug pharmacokinetic (PK) properties. For example, peptides grafted to the Fc region of an immunoglobulin G (IgG) utilize the FcRn recycling process to render a long circulating half-life to the peptide-Fc complex (delivery system based on Fc fusion protein). Besides, other delivery systems include those based on albumin, cell penetrating peptide (CPP), liposome, graphene oxide, hyaluronic acid, elastin-like polypeptide and peptide-SNAP-tag fusion protein are under development and evaluation actively.
Peptide-Fc fusions, also known as peptibodies, are an attractive alternative therapeutic format to monoclonal antibodies. They consist of biologically active peptides grafted onto an Fc domain of IgG. This approach retains certain essential features of antibodies, notably an increased apparent affinity through the avidity conferred by the dimerization of two Fcs and a long plasma residency time.
Fig.1 Peptibody and their mechanism of action.1
Albumin is the next generation drug delivery approach. It is the most abundant plasma protein in the transportation of nutrients in the body based on its multiple binding sites and long circulatory half-life (~19 days). Combining protein-based drugs with albumin is an elegant approach in which drugs are genetically fused to the N- or C-terminal or both ends of the albumin. The protein gene is attached to albumin and expressed in a suitable expression host, resulting in a single fusion protein. However, it is necessary that the linker and fused moiety do not interfere with the folding of albumin, so as to retain its functionality and long half-life.
Fig.2 Albumin-based drug delivery strategies.2
CPP is a promising tool and has presented applications for peptide and protein delivery into cells as well as crossing various epithelia or the blood-brain barrier (BBB). CPP-mediated delivery of peptides and proteins is based on covalent conjugation of the CPP to the cargo peptide or protein or via physical complexation obtained by simply bulk-mixing the CPP with its cargo. The CPP efficiency is associated with its physicochemical properties and the route of administration of its cargo, the specific barrier and the target cell. CPPs are considered as safe and efficient vectors for transcellular transport of peptide and protein cargoes.
Liposomes are a novel drug delivery system, which are vesicular structures consisting of bilayers phospholipids. They are microscopic vesicles enclosed entirely by a membrane consists of lipid bilayers. The goal of using liposomes for drug delivery is to deliver the drug at a rate directed by the needs of the body during the period of treatment and directly to the place of action. Liposomes are colloidal spheres including cholesterol non-toxic surfactants, sphingolipids, glycolipids, long chain fatty acids and membrane proteins and drug molecules.
Fig.3 Targeted delivery system based on liposome.
A novel photodynamic therapy (PDT) drug delivery and phototoxicity on/off nano-system based on graphene oxide (NGO) as the carrier is developed to implement targeting and attacking in cancer treatment. In the nanodrug, NGO is modified with the antibodies or peptides for tumor targeting. Pyropheophorbide-a (PPa) conjugated with polyethylene-glycol is used to induce phototoxicity covering the surface of the NGO. The PPa-NGO-drug effectively induces phototoxicity to kill cells. This promising system renders a potential alternative to drug delivery systems for cancer therapy.
We also provide other delivery systems to meet clients’ individual requirments, including delivery systems based on hyaluronic acid, elastin-like polypeptide, peptide-SNAP-tag fusion protein, polymeric microspheres and polymeric nanofibers.
Fig.4 Illustration of the synthesis of β-cyclodextrin–hyaluronic acid polymers grafted with Fe3O4–graphene oxide (CDHA–MGO) for targeted photo-chemotherapy of tumor cells.3
Features of Our Delivery Systems
-
Improve the pharmacokinetics and therapeutic efficacy
-
Reduce the toxicity of highly potent drugs
-
Prolonged plasma concentration
-
Optimized drug release rate in vivo
Experienced in antibody/peptide chemistry and with dedicated commitment to the scientific community, Creative Biolabs has perfected our technical pipelines in the development of diverse module delivery systems. We would like to share our knowledge and passion in this field to promote the advances of science and for a better tomorrow. Please contact us for more information and a detailed quote.
References
-
Jendryczko, Karolina, et al. "Drug conjugation via maleimide–thiol chemistry does not affect targeting properties of cysteine-containing anti-FGFR1 peptibodies." Molecular Pharmaceutics 19.5 (2022): 1422-1433.
-
Larsen, Maja Thim, et al. "Albumin-based drug delivery: harnessing nature to cure disease." Molecular and cellular therapies 4.1 (2016): 1-12.
-
Liang, Wenting, et al. "β-cyclodextrin–hyaluronic acid polymer functionalized magnetic graphene oxide nanocomposites for targeted photo-chemotherapy of tumor cells." Polymers 11.1 (2019): 133.
Our services are For Research Use Only. We do not provide services to individuals.
